Ozempic can cost about $900 a month, Wegovy can be around $1,300 a month, and Rybelsus can cost roughly $950. With insurance, you may pay less.

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

Wegovy, to be in pharmacies by the end of June, has been launched in a pen-injection format with strengths ranging from 0.25 ...

The quest for weight loss has taken a dramatic turn. A wave of new-age solutions, from once-weekly injectables like Wegovy ...

While both drugs belong to the GLP-1 receptor agonist class, Mounjaro has a dual mechanism (GIP and GLP-1), which clinical ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

Danish pharma giant Novo Nordisk’s announcement comes months after the launch of another top selling obesity drug Mounjaro in India by US based pharma giant Eli Lilly & Company.

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Universal access to GLP-1 receptor agonists for eligible populations could reduce global obesity prevalence by half and save ...

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.

Novo Nordisk has officially launched its anti-obesity drug Wegovy in India ahead of patent expiry. This move aims to tackle rising obesity rates while facing competition from rival drugs.